Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Bioverativ to Acquire Clinical-Stage Rare Disease Biotechnology Company, True North Therapeutics

BIOVERATIV INC COMMON (BIVV) 
Last bioverativ inc common earnings: 2/13 04:15 pm Check Earnings Report
Company Research Source: Business Wire
- Strengthens pipeline with lead candidate TNT009 in cold agglutinin disease, a rare and chronic autoimmune hemolytic anemia with no approved therapies - TNT009 granted breakthrough therapy designation by FDA; late-stage development planning underway - Advances Bioverativ’s vision of becoming the leading rare disease company focused on blood disorders - Conference call today at 8:30 a.m. ET WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV), a global biotechnology company focused on the discovery, development and commercialization of innovative therapies for hemophilia and other rare blood disorders, today announced that it has entered into a definitive agreement to acquire South San Francisco-based True North Therapeutics, a privately-held, clinical-stage rare disease biotechnology company, for an upfront payment of $400 million plus assumed cash. True Nor Show less Read more
Impact Snapshot
Event Time:
BIVV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for BIVV alerts
Opt-in for
BIVV alerts

from News Quantified
Opt-in for
BIVV alerts

from News Quantified